Recently approved treatments for generalized myasthenia gravis (gMG), including complement and neonatal Fc receptor (FcRn) ...

Heightened focus on delays in diagnosing generalized myasthenia gravis (gMG) follows the promise of better results for some patients with newer treatments that include complement inhibitors and ...

Sugammadex (Bridion; Merck) is a small-molecule oligosaccharide, also known as a modified gamma cyclodextin, that was ...

In part 4 of our interview, we learn more about nipocalimab’s safety profile and how this investigative agent might address ...

COUR Pharmaceuticals has been around a while, but not until last year did the company solidify behind its ultimate mission ...

THE occurrence of thyrotoxicosis in patients with myasthenia gravis is not rare, over 90 such cases having been reported since the turn of the century. 1,2 Various estimates place the incidence of ...

Biopharma doubles down on immunology and inflammation as companies target new pathways and seek to improve on current options ...

Overlap syndromes involving myasthenia gravis, myositis and myocarditis are recognised adverse effects of immune checkpoint inhibitors (ICI). We report a similar syndrome of myasthenia gravis and ...

Sanofi is still plugging away with its oral BTK inhibitor tolebrutinib in multiple sclerosis, but has decided to abandon efforts to develop the drug for neuromuscular disorder myasthenia gravis.

Heading into 2025, the chief item on argenx’s agenda is the FDA’s April 10 target action date to decide on the approval of a ...

Belgian biopharma UCB has been given the green light by the FDA for Zilbrysq as a treatment for generalised myasthenia gravis (gMG), one of two drugs that the company hopes will shake up the ...